Cureteq

Cureteq is a Swiss clinical-stage biotechnology company that employs an asset-centric "buy-and-build" strategy to develop innovative therapies. The company focuses on identifying and acquiring high-potential drug candidates from pharmaceutical and biotech partners, leveraging its expertise to advance them through clinical development. Its lead program, CTQ-001, is a potent and selective small molecule inhibitor of Protein Arginine Methyltransferase 5 (PRMT5), acquired from Janssen Pharmaceutica. CTQ-001 is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors and B-cell lymphomas. Cureteq is led by a management team with a proven track record in oncology and corporate development. The company aims to address significant unmet needs in cancer treatment by optimizing the development path for its acquired assets.